TRAVERE THERAPEUTICS, INC. Proceeds from (Payments for) Other Financing Activities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Proceeds from (Payments for) Other Financing Activities of $2.05 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2021-03-01
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for the quarter ending 2019-12-31 was $772.00K, a 15.54% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for the quarter ending 2019-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for the quarter ending 2018-12-31 was $914.00K, a 37.65% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for the quarter ending 2018-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for fiscal 2020 was $2.05M, a 15.14% increase from fiscal 2019.
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for fiscal 2019 was $1.78M, a 3.68% increase from fiscal 2018.
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for fiscal 2018 was $1.71M, a 158.13% increase from fiscal 2017.
- TRAVERE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for fiscal 2017 was $664.00K.
| Period end | Proceeds from (Payments for) Other Financing Activities 3 month | Proceeds from (Payments for) Other Financing Activities 6 month | Proceeds from (Payments for) Other Financing Activities 9 month | Proceeds from (Payments for) Other Financing Activities 12 month | Proceeds from (Payments for) Other Financing Activities 12 month as first filed | Proceeds from (Payments for) Other Financing Activities 34 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $2.05M 10-K · filed 2021-03-01 | |||||
| 2019-12-31 | $772.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $772.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.78M 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $1.00M 10-Q · filed 2019-10-30 | ||||
| 2019-06-30 | $1.00M 10-Q · filed 2019-08-06 | |||||
| 2018-12-31 | $914.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $914.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.71M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $800.00K 10-Q · filed 2019-10-30 | ||||
| 2018-06-30 | $800.00K 10-Q · filed 2019-08-06 | |||||
| 2017-12-31 | $664.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $664.00K derived: sum of 2 quarters · filed 2020-02-24 | $664.00K 10-K · filed 2020-02-24 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | ||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-03 | |||||
| 2016-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$213.00K derived: sum of 2 quarters · filed 2019-02-26 | -$359.00K 10-K · filed 2019-02-26 | $0.00 10-K · filed 2018-02-27 | ||
| 2016-09-30 | -$293.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$439.00K 10-Q · filed 2017-11-07 | ||||
| 2016-06-30 | -$146.00K 10-Q · filed 2017-08-09 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-07-06 | |||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$2.26M 10-Q · filed 2014-08-14 | ||||
| 2014-03-31 | -$2.26M 10-Q · filed 2014-05-15 | |||||
| 2013-12-31 | -$957.27K 10-K/A · filed 2015-07-09 | -$957.27K 10-K/A · filed 2015-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |